Eric Crombez
Known title: EVP and Chief Medical OfficerCIK: 0001653052
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Transaction History
| ABEO | ▼ Sell | Open Market | 26,143 | $145K | 5/15/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 344 | $9K | 5/5/2026 | View on chart |
| RARE | ▲ Buy | Grant | 34,674 | $0 | 4/16/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 7,029 | $160K | 3/2/2026 | View on chart |
| RARE | ▲ Buy | Grant | 11,643 | $0 | 3/1/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 16,284 | $83K | 2/2/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 37,313 | $0 | 1/26/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 4,718 | $33K | 8/14/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 520 | $20K | 5/5/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 242 | $8K | 4/21/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 8,945 | $377K | 3/3/2025 | View on chart |
| RARE | ▲ Buy | Grant | 16,813 | $0 | 3/1/2025 | View on chart |
| RARE | ▲ Buy | Grant | 14,971 | $0 | 3/1/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 36,101 | $0 | 1/31/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 11,044 | $0 | 8/13/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 354 | $15K | 5/2/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 142 | $6K | 4/18/2024 | View on chart |
| RARE | ▲ Buy | Grant | 19,400 | $0 | 3/1/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 1,238 | $67K | 3/1/2024 | View on chart |
| RARE | ▲ Buy | Grant | 4,658 | $0 | 5/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth
Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.